StoryResearch
Three-year Phase 3 EMBARK data shows Elevidys slows disease progression by 70-73% in ambulatory Duchenne patients
Three-year follow-up of ambulatory Duchenne patients treated with Elevidys showed sustained functional gains: 4.39-point improvement on North Star Ambulatory Assessment, 6-second improvement in time to rise, and 2.7-second improvement in 10-meter walk/run, representing 70-73% slowing of disease progression versus untreated controls.